Skip to main content
. 2007 Jun 5;104(24):10152–10157. doi: 10.1073/pnas.0702916104

Fig. 4.

Fig. 4.

Efficacy of TTFields treatment in recurrent GBM. (A) TTP of treated patients (n = 10); median TTP is 26.1 weeks (dashed black line). (B) Kaplan–Meier OS curve for NovoTTF-100A treated patients (n = 10). The median OS in these patients is 62.2 weeks (black dashed line), and the 1-year survival rate is 67.5% (blue dashed line).